Bryozoan Bugula Neritina - An Excellent Host As a Candidate Against Cancer and Other Illnesses
By Stephen L Bynum
Bryostatin cancer drugs are currently undergoing Phase L and Phase II cancer trials according to the U. S. National Institute of Health Clinical Trials program. Bryostatin cancer drugs are produced by the bacterium Candidatus endobugula sertula and are found in the marine bryozoan Bugula neritina. Bryozoans are water filter-feeders. There are over 5,000 species of bryozoans in the world with only about 50 freshwater species. The best source of the cytotoxic chemical bryostatin I was found in host bryozoans Bugula neritina in 1968. It has shown promise against lung cancer, prostate cancer, Non-Hodgkin's lymphoma, and possibly pancreatic cancer. Bryostatin cancer drugs act synergistically with other cancer drugs and are potent activators of Protein Kinase C.
Currently, over 20 types of bryostatins have been identified from the bryozoan Bugula neritina host. It currently takes about 14 tons of the bryozoan Bugula neritina to produce 1 ounce of bryostatin. The effective mechanism of bryostatin is its unique ability to activate the cell-signaling enzyme Protein Kinase C (PKC) resulting in the inhibition of tumor cell growth and causing tumor cell death. Bryostatin cancer drugs have been associated with initiating immune response, regulating cell growth activity, and in learning and memory. There are currently about 40 Phase 1 and Phase 2 clinical trials ongoing for the use of bryostatin cancer drugs for numerous cancers and in Alzheimer's patients.
I suggest you check out my other CANCER summary on:
- Reverse Your Cancer by Rebuilding Your Immune System With Natural Treatments
- Are There Truly Natural Cancer Cures?
- Gene Therapy and the Search For New Cures For Cancer
- Dogs May Hold Key to How to Fight Cancer
- Red Face Linked to Cancer of Esophagus
